Radionetics Oncology announces a strategic agreement with Lilly

Paul Grayson, CEO of Radionetics Oncology

Radionetics Oncology, a biotechnology company discovering and developing novel small molecule G protein coupled receptor (GPCR) targeted radiopharmaceuticals to treat a broad range of solid tumors, yesterday announced the formation of a strategic relationship with Eli Lilly and Company to take forward Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals. Under the terms of the agreement, […]